HumaDx Secures Tens of Millions in Series A1 Funding from Yuansheng Venture Capital to Advance Multiplex Flow Fluorescence Technology

Nanjing Human Zhizao Technology Co., Ltd. (hereinafter referred to as “Human Zhizao”) recently announced the completion of its RMB tens of millions Series A1 financing, exclusively invested by Genesis Capital, a well-known investment firm in the field of in vitro diagnostics (IVD). This marks another rapid round of financing for Human Zhizao within one year of its establishment, following its Pre-A round investment from Enran Venture Capital. The company has now accumulated nearly RMB 100 million in total funding. As an IVD company with profound technical expertise, a comprehensive product portfolio, and strong sales capabilities, Human Zhizao will utilize the proceeds from this financing round to promote the sales of its automated multiplex flow fluorescence detection platform and supporting reagents, fund the research, development, and registration of new product pipelines, and further expand its team. Qiangyun Capital served as the exclusive financial advisor for the Series A1 financing and will continue to oversee subsequent closings of the Series A round.

Human Zhizao Beijing Yizhuang Office Area

Flow cytometry-based fluorescence detection technology is a new-generation, high-throughput platform for simultaneous multi-analyte testing, and it currently represents one of the most prominent sectors in the field of in vitro diagnostics (IVD). Its application in immunology overcomes the limitation of chemiluminescence immunoassay, which is restricted to single-analyte detection. This technology offers advantages such as high throughput, high sensitivity, multiplexing capability, and cost-effectiveness. Highly aligned with the development trends of medical laboratory testing in China, it meets the growing demand for clinical diagnostics and has garnered widespread attention in the IVD market.

HumaPlex Fully Automated Multiplex Flow Fluorescence Luminescence Quantitative Detection Platform

Since entering the IVD industry in 2003, Mr. Li Dongqi, founder of Human Zhizao, has spent nearly two decades accumulating experience and advancing his career, starting as a regional distributor for IVD products and rising to become the President of HUMAN GmbH’s China region. He subsequently assembled an entrepreneurial team comprising renowned scientists, seasoned executives from prominent multinational corporations, and industry veterans to establish Human Zhizao. The company boasts a pragmatic team culture and a well-rounded skill set. Mr. Li possesses profound insights into industrial development trends and has formulated a clear and comprehensive strategic plan for the company’s future, with its R&D pipeline and marketing strategies demonstrating distinctive structure and methodology.

Regarding this financing round,Mr. Li Dongqi, Founder of Human ZhizaoNanjing Human Zhizao Technology Co., Ltd. stated: “Over the next three years, Human Zhizao will strive to become a leading enterprise in China in the field of fully automated multiplex flow fluorescence systems. As more startups and capital enter this sector, we believe the industry ecosystem will gradually mature, and an increasing number of application and testing needs will be uncovered. In recent years, the Human Zhizao team has collaborated with scientists both domestically and internationally to breakthrough and master stable microsphere preparation technologies, enabling the consistent supply of multiplex/ultra-multiplex magnetic encoded microspheres. We have also built a robust hardware R&D team and a high-quality reagent development team. The company’s product pipeline features numerous highlights, allowing for the development of new biomarkers aligned with clinical needs. Moving forward, Human Zhizao will maintain high efficiency, emphasize execution, and leverage its resource advantages in sales and marketing to build a diligent, pragmatic, healthy, and profitable enterprise. Here, Human Zhizao extends its gratitude to Genesis Capital and other institutions for their support and trust, as well as to existing shareholder Enran Venture Capital for its steadfast confidence.”

As the sole investor in this round of financing,Dr. Lin Yi, Managing Partner of Yuansheng Venture Capital“It stated: ‘Flow cytometry fluorescence technology boasts vast market potential. We continue to closely monitor this sector, identifying and supporting outstanding enterprises in their rapid growth. The team at Nanjing Human Zhizao Technology Co., Ltd. demonstrates well-balanced background and capabilities: its materials science R&D team has developed stable and reliable coded microsphere technology; the reagent development team exhibits strong execution; the instrument R&D team is diligent and efficient; and the marketing team brings extensive experience and broad channel coverage. Meanwhile, the company’s product pipeline is strategically structured, with clear market entry points for each product, laying a solid foundation for rapid market penetration. We are delighted to become shareholders of Nanjing Human Zhizao and are confident in its accelerated development!’”

Pre-Series A Investors,Dr. Chen Renhai, Founding Managing Partner of Enran VenturesEnran Venture Capital stated: “We have consistently maintained a positive outlook on and provided support for the growth potential of the sector in which Nanjing Human Zhizao Technology Co., Ltd. (Human Zhizao) operates, as well as for the comprehensive capabilities and market competitiveness of its founder and team. With the backing of Yuansheng Venture Capital, the lead investor in this financing round, we believe the company will be significantly empowered to advance its existing R&D pipeline and capture future market share with unstoppable momentum. Furthermore, it is particularly encouraging that, concurrently with this financing round, the company has efficiently completed a systematic integration of resources and channels on the sales front. This has rendered the company’s system and organizational structure more robust, laying a solid foundation for the smooth implementation of its subsequent strategic plans. Enran Venture Capital will continue to stand by the company, witnessing its successive leaps and rapid ascent.”

As the exclusive financial advisor for this round of financing,Mr. Liu Zhiqiang, General Manager of Qiangyun Capital“It was stated that, compared with other medical sectors, IVD products have a faster technology iteration cycle and shorter product development and time-to-market cycles. Therefore, there are very high demands for the ability to judge technological prospects, drive product development, and execute rapid market penetration. Mr. Li Dongqi, founder of Nanjing Human Zhizao Technology Co., Ltd., and its core team bring nearly 20 years of experience in the IVD industry, perfectly aligning with these requirements and providing a solid foundation for the company’s rapid growth. We are honored to have assisted Nanjing Human Zhizao in completing this round of financing, as well as acquiring a commercial company during the process, thereby expanding its sales network across China. We remain committed to supporting Nanjing Human Zhizao’s long-term development.”

Nanjing Human Zhizao Technology Co., Ltd. is a medical technology innovation company integrating R&D, production, and sales. Leveraging years of accumulated expertise in materials science, in vitro diagnostics (IVD), and marketing, and centered on its core multiplex flow fluorescence technology, the company is committed to providing clinical customers with fully automated, high-throughput, and highly competitive multiplex flow fluorescence detection platforms and accompanying reagents. It focuses on the diagnosis of major immune diseases, complex and refractory conditions, and rare diseases, while actively expanding into emerging blue-ocean markets within the IVD sector.

YuanSheng Capital is an investment firm focused on the early and growth stages of the healthcare sector, headquartered in Suzhou BioBAY with a global reach. To date, it has invested in over 160 outstanding companies in the life and health sectors, covering four key areas: novel drug development, medical devices, in vitro diagnostics and precision medicine, as well as healthcare services. The firm has achieved substantial investment returns, with 16 of its portfolio companies listed on capital markets such as the Hong Kong Stock Exchange and the STAR Market. YuanSheng Capital has been repeatedly recognized as one of the Top 10 venture capital funds in China’s healthcare sector and as one of the most active healthcare investment institutions in China. Bringing together seasoned professional investors and a team of world-class scientific advisors, YuanSheng Capital possesses extensive experience in entrepreneurship, venture capital, and corporate operations within the biopharmaceutical industry and beyond. Leveraging its professionalism, focus, and abundant industry resources, the firm is committed to becoming one of the most successful healthcare and pharmaceutical venture capital funds in China.

Enran Venture Capital, established in 2015, strategically invests in revolutionary new technologies and products across the global biomedical and healthcare industry chains, striving to become a specialized investment institution in the fields of biomedicine and healthcare. The company’s management team and investors possess extensive investment experience and deep industrial resources in the biomedical and healthcare sectors, while focusing on the commercial value generated by the integration of “life,” “health,” and “innovation.” Enran Venture Capital specializes in life sciences, healthcare, and innovation, and is committed to serving as an investor, partner, and co-founder to its portfolio companies.

Qiangyun Capital is a boutique investment bank specializing in the healthcare and medical sector, with offices in Beijing, Shanghai, and Hangzhou. It is renowned in the industry for its high efficiency, high success rate, and comprehensive services. The Qiangyun Capital team comprises professionals from boutique investment banks, accounting firms, biotechnology companies, and other related fields. Since its establishment, the firm has successfully assisted clients in securing hundreds of millions of yuan in financing, covering areas such as diagnostics, medical devices, digital health, biotechnology, new drug R&D, healthcare services, innovative payment solutions, and CXO.